[go: up one dir, main page]

WO2008106659A3 - Méthodes de traitement du trouble bipolaire, ainsi que du trouble de la mémoire et/ou de la déficience cognitive qui lui sont associés - Google Patents

Méthodes de traitement du trouble bipolaire, ainsi que du trouble de la mémoire et/ou de la déficience cognitive qui lui sont associés Download PDF

Info

Publication number
WO2008106659A3
WO2008106659A3 PCT/US2008/055562 US2008055562W WO2008106659A3 WO 2008106659 A3 WO2008106659 A3 WO 2008106659A3 US 2008055562 W US2008055562 W US 2008055562W WO 2008106659 A3 WO2008106659 A3 WO 2008106659A3
Authority
WO
WIPO (PCT)
Prior art keywords
memory
cognitive impairment
associated therewith
impairment associated
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/055562
Other languages
English (en)
Other versions
WO2008106659A2 (fr
Inventor
David Lowe
Christopher J Leonard
Vivo Michael De
Geoffrey Tombaugh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memory Pharmaceuticals Corp
Original Assignee
Memory Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharmaceuticals Corp filed Critical Memory Pharmaceuticals Corp
Publication of WO2008106659A2 publication Critical patent/WO2008106659A2/fr
Publication of WO2008106659A3 publication Critical patent/WO2008106659A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La présente invention concerne une méthode qui permet de traiter ou de prévenir chez un patient des épisodes mixtes et/ou maniaques liés au trouble bipolaire, ainsi qu'au trouble de la mémoire et/ou à la déficience qui lui sont associés. La méthode consiste à administrer audit patient une quantité efficace d'au moins un modulateur du canal calcique sélectionné dans le groupe constitué par: (1) amlodipine, bépridil, clévidipine, félodipine, isradipine, lacidipine, lercanidipine, manidipine, niguldipine, nilvadipine, nisoldipine, ou nitrendipine; ou 2) l'énantiomère R d'un composé de 1,4-dihydropyridine autre que (+)-isopropyl-2-méthoxyéthyl-4-(2-chloro-3-cyano-phényl)-1,4-dihydro-2,6-diméthyl-pyridine-3,5-dicarboxylate.
PCT/US2008/055562 2007-03-01 2008-02-29 Méthodes de traitement du trouble bipolaire, ainsi que du trouble de la mémoire et/ou de la déficience cognitive qui lui sont associés Ceased WO2008106659A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89245507P 2007-03-01 2007-03-01
US60/892,455 2007-03-01

Publications (2)

Publication Number Publication Date
WO2008106659A2 WO2008106659A2 (fr) 2008-09-04
WO2008106659A3 true WO2008106659A3 (fr) 2008-10-16

Family

ID=39721861

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055562 Ceased WO2008106659A2 (fr) 2007-03-01 2008-02-29 Méthodes de traitement du trouble bipolaire, ainsi que du trouble de la mémoire et/ou de la déficience cognitive qui lui sont associés

Country Status (1)

Country Link
WO (1) WO2008106659A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820691B2 (en) 2006-08-28 2010-10-26 Medipropharma, Inc. Indoloquinoline compounds as calcium channel blockers
WO2014052849A1 (fr) * 2012-09-28 2014-04-03 Elan Pharmaceuticals, Inc. Traitements combinés de troubles bipolaires

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567271A (en) * 1977-06-20 1986-01-28 Sandoz Ltd. Benzoxadiazoles and benzothiadiazoles
US6458808B1 (en) * 2000-12-20 2002-10-01 Osmotica Corp. Pharmaceutical composition for the treatment of cognitive cerebrovascular disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567271A (en) * 1977-06-20 1986-01-28 Sandoz Ltd. Benzoxadiazoles and benzothiadiazoles
US6458808B1 (en) * 2000-12-20 2002-10-01 Osmotica Corp. Pharmaceutical composition for the treatment of cognitive cerebrovascular disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SINGH ET AL.: "Renewed Interest in Calcium Channel as Antimania Agents in the Third Millenium", HONG KONG JOURNAL OF PSYCHIATRY, vol. 14, no. 2, 2004, pages 12 - 15 *
SKOLNICK: "New Pharmacological Strategies", 1997, HUMANA PRESS, TOTOWA, NEW JERSEY, ISBN: 0806034690, article PUCILOWSKI ET AL.: "Calcium Channel Antagonists in Mood Disorders, in Antidepressants", pages: 81 - 102 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US8889190B2 (en) 2013-03-13 2014-11-18 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10363224B2 (en) 2013-03-13 2019-07-30 Upsher-Smith Laboratories, Llc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9555005B2 (en) 2013-03-15 2017-01-31 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10172878B2 (en) 2013-03-15 2019-01-08 Upsher-Smith Laboratories, Llc Extended-release topiramate capsules

Also Published As

Publication number Publication date
WO2008106659A2 (fr) 2008-09-04

Similar Documents

Publication Publication Date Title
DE602004014635D1 (de) Zusammensetzungen enhaltend l-typ-calciumcanalblockern und cholinesterase-hemmern
NZ329556A (en) Use of a composition containing ramipril in instant release form and a dihydroxypyridine compound in sustained release form in treating hypertension
CY1109711T1 (el) Νεα κρυσταλλικη μορφη υδροχλωριουχου λερκανιδιπινης και διαδικασιες για την παρασκευη τους
WO2008106659A3 (fr) Méthodes de traitement du trouble bipolaire, ainsi que du trouble de la mémoire et/ou de la déficience cognitive qui lui sont associés
ATE515277T1 (de) Zusammensetzungen und verfahren zum beschichten von medizinischen implantaten
WO2006032026A3 (fr) Formulations cristallines injectables a action prolongee de metabolites d'estradiol et leurs procedes d'utilisation
WO2007092755A3 (fr) Traitement de l'insuffisance et de la deficience de vitamine d avec de la 25-hydroxyvitamine d2 et de la 25-hydroxyvitamine d3
WO2008005427A3 (fr) Compositions et procédés destinés au traitement de lésions de la coiffe des rotateurs
DE60143197D1 (de) Kristalline form von 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- ä2,3'ü bipyridinyl und herstellungsverfahren hierfür
AU2003257180A8 (en) Biocompatible phase invertable proteinaceous compostions and methods for making and using the same
SG196767A1 (en) Length of self-retaining suture and method and device for using the same
WO2003070749A3 (fr) Auto-assemblage de nanofibres amphiphiles peptidiques dans des conditions physiologiques
AU2003212158A1 (en) Amphiphilic diblock, triblock and star-block copolymers and their pharmaceutical compositions
WO2004069215A3 (fr) Compositions de blanchiment de dents et procedes
WO2000004862A3 (fr) Formulations bioameliorees comprenant de l'eprosartane dans des formes galeniques solides destinees a une administration orale
WO2006055603A3 (fr) Formulations injectables de nanoparticules d'olanzapine
WO2005000194A3 (fr) Procedes permettant de traiter des douleurs post-chirurgicales par administration d'un anticorps dirige contre le facteur de croissance neuronal, et compositions contenant cet anticorps
WO2007150074A3 (fr) Compositions comprenant du naproxène nanoparticulaire et de l'hydrocodone à libération contrôlée
AU2003229835A8 (en) Compounds, compositions and method for transporting cyclosporin molecules through the blood brain barrier
EP1192938A3 (fr) Composition favorisant la perméation d'agents dermiques topiques
WO2002094745A3 (fr) Composes de liaison de cyclophiline non peptidique et leurs utilisations
ATE455115T1 (de) 1,4-dihydropyridine-kondensierte heterocyclen verfahren zu deren herstellung sowie verwendung und zusammensetzungen dergleichen
PL364570A1 (en) Composition and method for controlled release injections
WO2006034001A3 (fr) Procedes de traitement de l'infection par vih
WO2019008516A3 (fr) Traitement du cancer avec des dihydropyridines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08731173

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08731173

Country of ref document: EP

Kind code of ref document: A2